DHSSPS Equality policies screened 1 July to 30 September 2015
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- Revision of appeal procedures set out in the Health and Social Care (Disciplinary Procedures) Regulations (Northern Ireland) 2014 (“the 2014 Regulations”)
- The New Firefighters’ Pension Scheme (Amendment) (No. 3) Order (NI) 2015
- Firefighters’ Pension Scheme Regulations (Northern Ireland) 2015
- Minimum care Standards for Nursing Homes
- NICE (Clinical) Guidelines NG8 - Anaemia management in people with chronic kidney disease. This guideline updates and replaces NICE guideline CG114
- NICE (Clinical) Guideline NG9 - Bronchiolitis in children
- NICE (Clinical) Guidelines NG10 - Violence and aggression (update)
- NICE (Clinical) Guidelines NG11 - Challenging Behaviour and Learning Disabilities
- NICE Guidelines NG12 - Suspected cancer: recognition and referral
- NICE (Clinical) Guideline NG14 - Melanoma: assessment and management
- NICE Guidelines PH50 - Domestic violence and abuse - how services can respond effectively
- NICE Technology Appraisal TA345 - Naloxegol for treating opioid induced constipation
- NICE Technology Appraisal TA346 - Aflibercept for treating diabetic macular oedema
- NICE Technology Appraisal TA347 - Nintedanib for previously treated locally advanced, metastatic or locally recurrent non-small cell lung cancer
- NICE Technology Appraisal TA348 - Everolimus for preventing organ rejection in liver transplantation
- NICE Technology Appraisal TA349 - Dexamethasone intravitreal implant for treating diabetic macular oedema
- NICE Technology Appraisal TA350 - Secukinumab for treating moderate to severe plaque psoriasis
- NICE Technology Appraisal TA352 - Vedolizumab for the treatment of adult patients with moderately to severely active Crohn’s disease
- NICE Technology Appraisal TA 354 - Edoxaban tosylate for the treatment and secondary prevention of deep vein thrombosis and pulmonary embolism